Aclaris Therapeutics (ACRS) vs Immix Biopharma (IMMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immix Biopharma (IMMX) has outperformed Aclaris Therapeutics (ACRS) over the past year, gaining 60.7% versus a gain of 37.1%. Immix Biopharma is the larger company by market cap ($583.3 million vs $545.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | IMMX |
|---|---|---|
| Share price | $3.44 | $6.96 |
| Market cap | $545.63M | $583.33M |
| 1-day change | -1.71% | -1.14% |
| YTD return | +14.29% | +33.08% |
| 1-year return | +37.05% | +60.74% |
| 5-year return | -72.74% | — |
| EPS (TTM) | $-0.59 | $-0.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.83M | — |
| Revenue growth (YoY) | -58.19% | — |
| Net income (latest FY) | $-64.92M | $-29.40M |
| Gross margin | 73.28% | — |
| Operating margin | -975.91% | — |
| Net margin | -829.58% | — |
| 52-week high | $6.60 | $15.10 |
| 52-week low | $2.46 | $3.78 |
| Distance from 52-week high | -47.88% | -53.91% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +205.23% | +243.82% |
| Average volume | 3.07M | 1.45M |
| Shares outstanding | 158.61M | 83.81M |
| Employees | 69 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMX has outperformed ACRS by 23.7 percentage points over the past year.
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Immix Biopharma
IMMX stock →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
ACRS vs IMMX FAQ
Which is bigger, Aclaris Therapeutics or Immix Biopharma?
Immix Biopharma (IMMX) is larger, with a market capitalization of $583.33M compared with $545.63M for Aclaris Therapeutics (ACRS).
Which stock has performed better over the past year, ACRS or IMMX?
IMMX returned +60.74% over the past 12 months, compared with +37.05% for ACRS (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and Immix Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.